AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, ...

AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca (LSE:AZN) recently reported robust earnings results, with significant year-over-year increases in sales, revenue, ...

Imfinzi is already a massive moneymaker for AstraZeneca. It's an immuno-oncology drug that helps the immune system find tumor cells camouflaging themselves behind a common protein called PD-L1.

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca (NASDAQ:AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of muscle-invasive bladder cancer, or MIBC. The analysis showed ...

Also Read: AstraZeneca’s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients Patients were treated with neoadjuvant Imfinzi in combination with chemotherapy ...

AstraZeneca strives to redefine cancer care and help transform outcomes for patients with IMFINZI as a monotherapy and in combination with IMJUDO as well as other novel immunotherapies and modalities.

(RTTNews) - AstraZeneca (AZN.L, AZN) said Imfinzi or durvalumab in combination with chemotherapy has been recommended for approval in the European Union for the treatment of adults with resectable ...